for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tscan Therapeutics Inc

TCRX.OQ

Latest Trade

8.75USD

Change

0.02(+0.23%)

Volume

2,526

Today's Range

8.53

 - 

8.85

52 Week Range

6.07

 - 

14.71

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.73
Open
8.53
Volume
2,526
3M AVG Volume
1.50
Today's High
8.85
Today's Low
8.53
52 Week High
14.71
52 Week Low
6.07
Shares Out (MIL)
23.77
Market Cap (MIL)
207.49
Forward P/E
-1.27
Dividend (Yield %)
--

Latest Developments

More

TScan Therapeutics Reports Third Quarter 2021 Financial Results

TScan Therapeutics Reports Q2 Loss Per Share Of $7.69

Tscan Therapeutics, Inc. Announces Pricing Of Initial Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tscan Therapeutics Inc

TScan Therapeutics, Inc. (TScan), along with its wholly owned subsidiary, TScan Securities Corporation is a biotechnology company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation (HCT). TSC-100 and TSC-101 targets histocompatibility antigens (HA)-1 and HA-2 antigens, respectively. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. Its TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors. The Company's platform technologies include TargetScan, ReceptorScan and T-Integrate.

Industry

Business Services

Contact Info

830 Winter Street

WALTHAM, MA

02451

United States

+1.857.3999500

https://www.tscan.com

Executive Leadership

David P. Southwell

Chief Executive Officer, Director

Gavin MacBeath

Chief Scientific Officer

Shane Maltbie

Vice President - Finance

Ann Hargraves

Vice President - Human Resources

Heather Savelle

Vice President of Investor Relations

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-6.900
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.67
Price To Book (MRQ)
1.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up